144 related articles for article (PubMed ID: 10819574)
1. Effective repeat administration with adenovirus vectors to the muscle.
Chen P; Kovesdi I; Bruder JT
Gene Ther; 2000 Apr; 7(7):587-95. PubMed ID: 10819574
[TBL] [Abstract][Full Text] [Related]
2. Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).
Perrin LA; June JE; Rosebury W; Robertson A; Kovesdi I; Bruder JT; Kessler PD; Keiser JA; Gordon D
Gene Ther; 2004 Mar; 11(6):512-21. PubMed ID: 14999223
[TBL] [Abstract][Full Text] [Related]
3. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration.
Price AR; Limberis MP; Wilson JM; Diamond SL
Gene Ther; 2007 Nov; 14(22):1594-604. PubMed ID: 17898795
[TBL] [Abstract][Full Text] [Related]
5. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
Parks R; Evelegh C; Graham F
Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice.
Yoon SK; Armentano D; Wands JR; Mohr L
Cancer Gene Ther; 2001 Aug; 8(8):573-9. PubMed ID: 11571535
[TBL] [Abstract][Full Text] [Related]
7. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice.
Bouchard S; MacKenzie TC; Radu AP; Hayashi S; Peranteau WH; Chirmule N; Flake AW
J Gene Med; 2003 Nov; 5(11):941-50. PubMed ID: 14601131
[TBL] [Abstract][Full Text] [Related]
8. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.
Moffatt S; Hays J; HogenEsch H; Mittal SK
Virology; 2000 Jun; 272(1):159-67. PubMed ID: 10873758
[TBL] [Abstract][Full Text] [Related]
9. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle.
Löser P; Hillgenberg M; Arnold W; Both GW; Hofmann C
Gene Ther; 2000 Sep; 7(17):1491-8. PubMed ID: 11001369
[TBL] [Abstract][Full Text] [Related]
10. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.
Tsai V; Johnson DE; Rahman A; Wen SF; LaFace D; Philopena J; Nery J; Zepeda M; Maneval DC; Demers GW; Ralston R
Clin Cancer Res; 2004 Nov; 10(21):7199-206. PubMed ID: 15534093
[TBL] [Abstract][Full Text] [Related]
11. Repeated administration of adenovector in the eye results in efficient gene delivery.
Hamilton MM; Brough DE; McVey D; Bruder JT; King CR; Wei LL
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):299-305. PubMed ID: 16384977
[TBL] [Abstract][Full Text] [Related]
12. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
Rivière C; Danos O; Douar AM
Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
[TBL] [Abstract][Full Text] [Related]
13. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
[TBL] [Abstract][Full Text] [Related]
14. Variation in the immune response to adenoviral vectors in the brain: influence of mouse strain, environmental conditions and priming.
Ohmoto Y; Wood MJ; Charlton HM; Kajiwara K; Perry VH; Wood KJ
Gene Ther; 1999 Apr; 6(4):471-81. PubMed ID: 10476207
[TBL] [Abstract][Full Text] [Related]
15. Localized gene delivery using antibody tethered adenovirus from polyurethane heart valve cusps and intra-aortic implants.
Stachelek SJ; Song C; Alferiev I; Defelice S; Cui X; Connolly JM; Bianco RW; Levy RJ
Gene Ther; 2004 Jan; 11(1):15-24. PubMed ID: 14681693
[TBL] [Abstract][Full Text] [Related]
16. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen MT; Kanerva A; Hemminki A
Gene Ther; 2008 Jun; 15(12):921-9. PubMed ID: 18401431
[TBL] [Abstract][Full Text] [Related]
17. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse.
Ye X; Robinson MB; Pabin C; Batshaw ML; Wilson JM
Gene Ther; 2000 Oct; 7(20):1761-7. PubMed ID: 11083498
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
19. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.
Mitchell M; Jerebtsova M; Batshaw ML; Newman K; Ye X
Gene Ther; 2000 Dec; 7(23):1986-92. PubMed ID: 11175309
[TBL] [Abstract][Full Text] [Related]
20. Identification of multiple genetic loci that regulate adenovirus gene therapy.
Zhang HG; Hsu HC; Yang PA; Yang X; Wu Q; Liu Z; Yi N; Mountz JD
Gene Ther; 2004 Jan; 11(1):4-14. PubMed ID: 14681692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
